Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.…
Amarin: 3 Key Takeaways for Long-Term Investors
Amarin (NASDAQ: AMRN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 80 employees.
The shares were at 10.57 USD on 20 November 2026, down 34.8% over 52 weeks. Its 52-week range is 10.55 USD to 17.31 USD, and it trades at the bottom of that range.
Its market capitalisation is 444.39M USD.
Amarin reports return on equity of -8.4%, an operating margin of -14.0% and revenue down 20.4% year over year.
It holds more cash than debt, a net cash position of 315.77M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 13.00 USD is 23.0% above the current price. The next earnings report is expected on 24 February 2027.